JUN 06, 2022 9:30 AM PDT

New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis

WRITTEN BY: Annie Lennon

A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The corresponding study was published in PLOS Biology

Each year, around 1.5 million people die from Mycobacterium tuberculosis infection. Although antibiotics exist to treat the bacteria, multi-drug resistant, extensively drug-resistant, and totally drug-resistant strains have developed, and pose a significant health risk.

For the current study, researchers screened a variety of plant extracts to find a new antibiotic capable of treating drug-resistant tuberculosis. They ultimately found deoxypergularinine (DPG), a compound purified from the root of Cynanchum atratum- a flowering plant used in traditional Chinese medicine- that exhibited promising antibacterial activity. 

The researchers created multiple analogs of DPG and tested them for their ability to inhibit M. tuberculosis without harming infected cells. In doing so, they identified a class of derivatives with antitubercular effects and low toxicity. 

They then tested these derivatives on mouse models. Four weeks of treatment with one derivative, known as PP1S, significantly reduced TB infection compared to a control group. The derivative also produced no clinical side effects in healthy rats after two weeks of high-dose treatment. 

Alongside PP1S, the researchers tested a second derivative, PP2S, in mice and found that, likewise, it produced no clinical side effects in healthy rats after two weeks. It also produced no adverse effects after four weeks of intermediate-dose therapy. 

They further noted that after a week of treatment with PP2S, mice underwent no significant changes in their gut microbiome, while other TB drugs produced multiple changes. This effect, says the researchers, is likely as PPS targets a gene called PE_PGRS57, which is found in few species of bacteria. 

"While further testing will be required, the low effective dose and high level of safety in these early tests indicate that these new drugs are likely to be important alternatives to the current regimen for treatment of tuberculosis," said Ho-Yeon Song of Soonchunhyang University in the Republic of Korea, one of the study’s authors, "A new class of PP derivatives is a M. tuberculosis-targeted antimicrobial with microbiome-safe properties."

 

Sources: Science DailyPLOS Biology

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 07, 2022
Cell & Molecular Biology
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
JUN 07, 2022
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
Labroots hosted its 6th Annual Laboratory Automation Virtual Event on May 18, 2022. The speaker roster for this free con ...
JUL 22, 2022
Coronavirus
Researchers Say Nasal Boosters Will be Important to Stopping COVID
JUL 22, 2022
Researchers Say Nasal Boosters Will be Important to Stopping COVID
The SARS-CoV-2 virus has continued to evolve since the start of the pandemic, and we've moved down the list of variants ...
JUL 24, 2022
Microbiology
Host Cell Proteins That Aid Lassa Virus & A Way to Stop One of Them
JUL 24, 2022
Host Cell Proteins That Aid Lassa Virus & A Way to Stop One of Them
Lassa virus infections are asymptomatic in about 80 percent of people. But the virus also causes Lassa fever (LF), which ...
AUG 11, 2022
Clinical & Molecular DX
New Tuberculosis Vaccine Enters Phase III Clinical Trial
AUG 11, 2022
New Tuberculosis Vaccine Enters Phase III Clinical Trial
Tuberculosis is a disease caused by the bacterium Mycobacterium tuberculosis. It is spread through the air when a person ...
AUG 09, 2022
Immunology
New Small Molecule May Improve Immunotherapy for a Variety of Cancers
AUG 09, 2022
New Small Molecule May Improve Immunotherapy for a Variety of Cancers
Scientists have been trying to stimulate the immune system to fight cancer for decades, and recent years have brought ma ...
Loading Comments...